List view / Grid view
3 September 2014 | By Boehringer Ingelheim
New data presented indicate that kidney function decline is less pronounced in patients with an irregular heartbeat who are treated with Pradaxa® (dabigatran etexilate) compared to warfarin...
1 September 2014 | By Boehringer Ingelheim
The European Respiratory Society International Congress, in Munich, Germany, September 6-10, 2014 sets the scene for important announcements across the substantial Boehringer Ingelheim respiratory portfolio...
19 August 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that the first patients have been enrolled in the company’s new international phase III study, RE-DUAL PCI™...
11 August 2014 | By Boehringer Ingelheim
The research-driven pharmaceutical company Boehringer Ingelheim overcame major challenges in the first half of 2014...
4 August 2014 | By Boehringer Ingelheim
Boehringer Ingelheim today announced the U.S. Food and Drug Administration (FDA) approved two different products at the end of last week.
22 July 2014 | By Boehringer Ingelheim
...to investigate new therapeutic concepts in the field of ubiquitin signalling biology.
17 July 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that for the first time the U.S. Food & Drug Administration has granted Breakthrough Therapy designation for a treatment in idiopathic pulmonary fibrosis...
9 July 2014 | By Boehringer Ingelheim
Results from a Phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia aged 65 or older and ineligible for intensive remission induction therapy, lived longer...
7 July 2014 | By Boehringer Ingelheim
This year's Boehringer Ingelheim FENS Award was granted to Judit Makara from the Institute of Experimental Medicine of the Hungarian Academy of Sciences in Budapest, Hungary...
2 July 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced submission of Marketing Authorisation Applications in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol in the Respimat® Soft Mist™ Inhaler...
30 June 2014 | By Boehringer Ingelheim
The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to the investigational antidote idarucizumab...
23 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces a new study of Pradaxa® (dabigatran etexilate) in patients with atrial fibrillation...
17 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company presented results of two Phase III clinical trials studying the efficacy and safety of empagliflozin...
6 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that Pradaxa® (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism...
4 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that by a letter dated June 2, the United States Food and Drug Administration has informed the Company about the closure of the Warning Letter...
